RAPS: Cancer Drugs First to Take Advantage of UK Early Access Scheme

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a second product under a new accelerated review process intended to make promising new drugs available to patients more quickly. The drug, Bristol Myers Squibb\'s Opdivo (nivolumab), joins Merck\'s Keytruda (pembrolizumab) as one of two products listed under MHRA\'s early access to medicines scheme (EAMS), both of which are intended to treat advanced melanoma.